logo
After deaths, advocates raise concerns at vigil outside women's prison

After deaths, advocates raise concerns at vigil outside women's prison

Yahoo24-03-2025

Kelly O'Keefe Boettcher holds a photo of Brittany Doescher at a vigil near Taycheedah Correctional Institution in Fond du Lac on March 22, 2025 | Photo by Andrew Kennard/Wisconsin Examiner
At a vigil across the road from Taycheedah Correctional Institution in Fond du Lac, Wis., advocates sought to increase attention on the women's prison.
'There's been a lot of publicity with what goes on in the men's prisons in the last couple of years, but that is something that is not just within those prisons, it is at the women's prisons too,' Juli Bliefnick, who was once incarcerated at Taycheedah, said at the vigil.
The small group of advocates met in a neighborhood near the prison and walked up to the facility, carrying signs bearing photos of two women.
Wisconsin Watch and Wisconsin Public Radio published an article on March 11 that reported the deaths of Shawnee Reed, 36, on Feb. 23, and Brittany Doescher, 33, on March 6, following hospital stays. The women were incarcerated at Taycheedah Correctional.
Bliefnick is the operations coordinator for FREE, a nonprofit addressing the gender-specific issues of women's incarceration and reentry to society. She spoke about getting 'some visibility for these women and honor[ing] their memory' and showing support for women currently incarcerated at the facility.
The official causes of the deaths are still not public, according to the article. Family members said hospital staff linked the deaths to pneumonia. Following discussions with doctors, an unnamed family member of Doescher believes earlier treatment could have prevented her death. Family members said both women started mentioning health issues over the phone around a month before the article's publication on March 11.
The obituary for Doescher says that she 'suffered and died from complications from pneumonia left untreated.'
In a statement to Wisconsin Watch and WPR, Department of Corrections communications director Beth Hardtke said the agency was taking steps to prevent the spread of respiratory illnesses to staff and incarcerated people in a time of reportedly high numbers of respiratory illness cases in Wisconsin, the article said. She detailed actions taken by the department and said people incarcerated at Wisconsin prisons, including Taycheedah, recently received testing and treatment for Influenza A.
Another advocate at the vigil, Melissa Ludin, said she is a member of FREE's board.
'And I think if anything, I think there's things that really need to be looked into with that,' she said, referring to Doescher's family saying the cause of her death was untreated pneumonia. '…Are there other women that are sick?'
Cellmate homicide
In July 2023, Cindy Schulz-Juedes, 68, died at Taycheedah Correctional. Taylor Sanchez, 29 and also incarcerated at Taycheedah, was charged with first-degree intentional homicide of her cellmate. A jury trial is scheduled for July and early August.
In early March, the Examiner sent a records request for any reports produced by the Fond du Lac Police Department's investigation into Schulz-Juedes's death. The department denied the request on the grounds that disclosure could interfere with an ongoing prosecution or investigation.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System

Business Upturn

time06-06-2025

  • Business Upturn

LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System

CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) — LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX Diagnostics Chris Hole [email protected] Scius Communications Katja Stout+44 778 943 5990 [email protected]

LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System

Yahoo

time06-06-2025

  • Yahoo

LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System

CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX DiagnosticsChris Holeenquires@ Scius CommunicationsKatja Stout+44 778 943 5990katja@ Daniel Gooch+44 774 787 5479daniel@ _____________________1 This LEX Diagnostics product is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. It is not available for sale or distribution in the U.S., the U.K. or any other jurisdiction. All product descriptions, data, or discussions are preliminary, subject to change, and do not represent final or FDA-approved claims, indications, or labeling.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store